info:eu-repo/semantics/article
Therapeutic potential of ibuprofen inhalation for COVID-19 pneumonia: Report of two first cases
Fecha
2021-10Registro en:
Ambasch, German; Coscia, Esteban; Tambini Díaz, Jorge Luis; Bueno, Germán David; Argañarás, Luis Alberto; et al.; Therapeutic potential of ibuprofen inhalation for COVID-19 pneumonia: Report of two first cases; Journal of Clinical Images and Medical Case Reports; Journal of Clinical Images and Medical Case Reports; 2; 5; 10-2021; 1-5
2766-7820
CONICET Digital
CONICET
Autor
Ambasch, German
Coscia, Esteban
Tambini Díaz, Jorge Luis
Bueno, Germán David
Argañarás, Luis Alberto
Martínez Ríos, Nicolás
Porta, Daniela Josefina
Beltramo, Dante Miguel
Garcia, Nestor Horacio
Resumen
No specific and effective antiviral treatment has been approved for COVID-19 so far. Systemic corticosteroid and remdesivir have shown to decrease mortality in COVID-19 patients, but mortality still is elevated. We propose that nebulized hypertonic ibuprofen solu- tion which has bactericidal, virucidal, mucolytic and anti-inflamma- tory properties to be used for COVID-19 pneumonia and prevent the classical evolution to respiratory failure and mechanical respiration. We report here the first two cases of the COVID-19 pneumonia suc- cessfully treated with nebulized hypertonic ibuprofen solution (NaI- HS). Rationale of the treatment is to mitigate the local inflammation with inhaled NIH that stays in the lung and may inhibit proliferation of the virus, inflammation and successfully reverts the hypoxia ob- served in these clinical cases. Mild adverse events were observed. Larger and further studies are warranted to confirm the result of these cases.